<DOC>
	<DOCNO>NCT02031276</DOCNO>
	<brief_summary>This study proof concept , multi-center , randomize , double-blind , placebo-controlled , parallel-group phase 2 dose-ranging study BI 655066/ABBV-066 ( risankizumab ) , IL-23 p19 antagonist monoclonal antibody , patient moderately severely active Crohn 's disease .</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics BI 655066/ABBV-066 ( Risankizumab ) Patients With Active , Moderate-to-severe Crohn 's Disease .</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Men woman 1875 year time consent . 2 . Diagnosis Crohn 's disease least 3 month prior screen . 3 . Moderate severe active Crohn 's disease , define CDAI &gt; or=220 &lt; or=450 . 4 . Presence mucosal ulcer least one segment ileum colon CDEIS score &gt; 4 , assess ileocolonoscopy confirm central independent reviewer randomization 5 . Patients naive experience 1 TNF antagonist ( infliximab , adalimumab , certolizumab pegol ) dose approve Crohn 's Disease.TNF antagonist experience patient may stop antiTNF treatment due primary secondary nonresponsiveness , intolerance reason . 6 . Female patient : Women childbearing potential ( surgically sterilize menarche 1 year postmenopause ) , , sexually active agree use one appropriate medically accept method birth control addition consistent correct use condom date screen 15 week last administration study medication . Medically accept method contraception : ethinyl estradiol contain contraceptive , diaphragm spermicide substance , intrauterinedevice , 1 . Surgically sterilized female patient documentation prior hysterectomy , tubal ligation complete bilateral oophorectomy , 2 . Postmenopausal woman postmenopausal define permanent cessation = 1 year previously occur menses , 3 . Negative serum ßHuman Chorionic Gonadotrophin ( ßHCG ) test screen urine pregnancy test prior randomization . Male patient : 1. Who document sterile , 2. Who consistently correctly use effective method contraception ( i.e . condom ) study 15 week last administration study medication . 7 . Have capacity understand sign inform consent form . 8 . Be able adhere study visit schedule protocol requirement . Exclusion criterion : 1 . Have complication Crohn´s Disease strictures , stenosis , short gut syndrome , manifestation might require surgery , could preclude use CDAI ass response therapy , would possibly confound evaluation benefit treatment BI 655066 . 2 . Have current prior abscess , unless drain treat least 6 week prior randomization anticipate require surgery . Patients active fistula may include anticipation need surgery currently abscesses present . 3 . Have kind bowel resection diversion within 6 month intraabdominal surgery within 3 month prior screen . Patients current ileostomy colostomy exclude . 4 . Have receive treatment : Total parenteral nutrition ( TPN ) within 2 week screen . Any dose ustekinumab ( Stelara® ) . AntiTNF therapy = 8 week prior first administration study medication biologic = 8 week prior first administration study drug within 5 time halflife biologic prior first administration study agent , whichever longer . Natalizumab , efalizumab , agent deplete B T cell ( e.g. , rituximab , alemtuzumab , visilizumab ) within 6 month screen , , receive agent , evidence available screen persistent depletion target lymphocyte population . Any investigational drug within previous 4 week 5 time halflife investigational agent prior first administration study agent , whichever longer . Regular daily use opioids medical reason within previous 3 month prior first administration study agent . Rectal 5ASA compound , parenteral rectal corticosteroid must discontinue least 4 week prior visit 2 . Can adhere concomitant medication requirement specify section 4.2.2 . 5 . Are pregnant , nursing , plan pregnancy ( men woman ) enrol study , within 15 week receive last dose study medication . 6 . Have use apheresis ( e.g. , Adacolumn apheresis ) = 2 week prior screen . 7 . Have receive live bacterial viral vaccination = 12 week prior Day 1 . Patients must agree receive live virus bacterial vaccination study 12 month last administration study drug . 8 . Have Bacille CalmetteGuérin ( BCG ) vaccination within 12 month screen . Patient must agree receive BCG vaccination study 12 month last study drug administration . 9 . Have sign symptom infection , history chronic recurrent infection , evidence active herpes zoster infection &lt; 8 week screen , sool culture examination positive enteric pathogen , history latent active granulomatous infection , infect HIV virus , HepB HepC virus , establish nonserious infection 10 . Are eligible accorging TB screen criterion 11 . Have severe , progressive uncontrolled renal , hepatic , hematological , endocrine , pulmonary , cardiac , neurologic , cerebral psychiatric disease sign symptom . 12 . Have transplant organ 13 . Have know history lymphoproliferative disease 14 . Have malignancy history malignancy 15 . Have previously undergone allergy immunotherapy 16 . Are unable unwilling undergo multiple venipuncture 17 . Are known substance abuse 18 . Are currently intend participate study 19 . Have screen laboratory test result within protocol state parameter 20 . Have know hypersensitivity study drug 21 . Have evidence current previous clinically significant disease , medical condition CD , find medical examination lab value .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>